Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01, Bloomberg Earnings reports. Matinas BioPharma Holdings had a negative return on equity of 143.22% and a negative net margin of 8,834.65%.

Shares of Matinas BioPharma Holdings (MTNB) traded up $0.02 during trading hours on Friday, hitting $1.19. The stock had a trading volume of 66,584 shares, compared to its average volume of 348,032. Matinas BioPharma Holdings has a one year low of $1.01 and a one year high of $3.99.

A number of research analysts recently weighed in on the company. ValuEngine downgraded Matinas BioPharma Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. Maxim Group set a $6.00 price objective on Matinas BioPharma Holdings and gave the company a “buy” rating in a research note on Tuesday, August 8th. Finally, Roth Capital set a $9.00 price objective on Matinas BioPharma Holdings and gave the company a “buy” rating in a research note on Thursday, August 10th.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/17/matinas-biopharma-holdings-inc-mtnb-posts-quarterly-earnings-results-beats-expectations-by-0-01-eps.html.

In related news, Director Adam K. Stern purchased 100,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were acquired at an average price of $1.38 per share, with a total value of $138,000.00. Following the purchase, the director now directly owns 793,992 shares in the company, valued at $1,095,708.96. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have bought a total of 110,000 shares of company stock worth $151,250 in the last three months.

About Matinas BioPharma Holdings

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Earnings History for Matinas BioPharma Holdings (NYSEAMERICAN:MTNB)

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.